ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded to Buy at StockNews.com
StockNews.com upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) from a hold rating to a buy rating in a report issued on Wednesday. Several other brokerages have also commented on ACAD. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of ACADIA Pharmaceuticals in a research report […]
StockNews.com upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) from a hold rating to a buy rating in a report issued on Wednesday. Several other brokerages have also commented on ACAD. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of ACADIA Pharmaceuticals in a research report […]
